Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-748-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
No repeated dose toxicity data are available for the registered substance, therefore this endpoint is addressed using weight of evidence for a number of related substances. Based on the available data, the overall 28-day NOAEL for male and female rats is judged to be 200 mg/kg bw/day, based on observations in the liver and kidneys at higher dose levels.
There are no data for the dermal and inhalation routes.
There is a testing proposal for a 90 -day repeated dose toxicity test with polysulfides, bis[3-(triethyoxysilyl)propyl (CAS No 211519-85-6).
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 07.02.2000 to 26.07.2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods
- Qualifier:
- according to guideline
- Guideline:
- other: partial revision of 'Test method of new chemical substances' in Kanpogyo No. 700, Yakuhatsu No. 1039 and 61 kikyoku No. 1014 dated 5th Dec 1986
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Japan Inc.
- Age at study initiation: Five weeks
- Weight at study initiation: Males: 126.7-142.5 g; Females: 113.4-125.5 g
- Fasting period before study: No data
- Housing: Individually in stainless steel cages with wire floors
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: Yes, but period not specified
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 ±2
- Humidity (%): 55 ±10
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 07.02.2000 to 26.07.2000 - Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Test substance was accurately weighed and dissolved in olive oil. The mixture of 0.08, 0.4 and 2 % w/v were made from 10% w/v mixture by dilution. The 10% mixture was prepared once per week and dilutions were conducted later.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Olive oil used as TS not stable in water
- Concentration in vehicle: 10, 2, 0.4 and 0.08% w/v
- Amount of vehicle (if gavage): Total volume doses: 10 ml/kg
- Lot/batch no. (if required): 011OOA
- Purity: No data - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily (7 days/week)
- Dose / conc.:
- 8 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 40 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Six
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: A repeated dose 14-day pretest was conducted using doses of 50, 250 and 1000 mg/kg bw/day. Adverse effects were observed at all doses. Therefore the doses were adjusted for the current 28-day study to try and determine a NOAEL.
- Rationale for selecting satellite groups: To investigate reversibility of effects
- Post-exposure recovery period in satellite groups: 14 day post-exposure group for control and 1000 mg/kg bw/day groups - Positive control:
- No positive control
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least one per day for general clinical observations. At least twice per day for mortality.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once before start of exposure and then once per week (all groups, except recovery groups)
BODY WEIGHT: Yes
- Time schedule for examinations: Day prior to start of exposure, then on day 1 (at 1st administration), 3, 8, 12, 17, 21, 26, 28 during the administration period, and on day 1, 5, 10 and 14 during the recovery period.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of treatment and recovery periods
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: Yes
- How many animals: All
- Parameters checked in table No.1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of treatment and recovery periods
- Animals fasted: Yes
- How many animals: All
- Parameters checked in table No.1 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: On the last day of of administration and recovery periods (16 hour collection prior to scheduled sacrifice)
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked in table No.1 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Fourth week of exposure period and second week of recovery period
- Dose groups that were examined: All
- Battery of functions tested: Sensory activity to different types of stimulation, grip strength and locomotor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 2)
HISTOPATHOLOGY: Yes (see table 2) - Other examinations:
- None reported.
- Statistics:
- All data were evaluated with Bartlett's test for an equal variance and if the equality of variance was valid at 5% confidence limit, ONE-way ANOVA was used. If significant differences were obtained with ANOVA, data from control and treatment groups were compared by Dunnett test. If the equality of variance was no established, Kruskal-Wallis test was used. If significant differences were obtained, data from control and treatment groups were compared by nonparametric Dunnett test. Furthermore, FOB data were analysed with Kruskal-Wallis test, and if significant difference was obtained, data were further analysed with nonparametric Dunnett test.
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: There were no deaths related to treatment. Clinical signs were salivation and staining around the nose and mouth. Salivation was observed in all dose groups, and is generally associated with gavage dosing.
BODY WEIGHT AND WEIGHT GAIN: No adverse effects.
FOOD CONSUMPTION: No adverse effects.
HAEMATOLOGY: Haematological examinations revealed an increase in prothrombin time and activated partial thromboplastin time in the males of the 1000 mg/kg bw/day group at the end of the treatment period. Changes were thought to be secondary to effects on the liver.
CLINICAL CHEMISTRY: Blood chemistry tests revealed an increase in total proteins and albumin in males and females, an increase in calcium in males, an increase in gamma-GPT, GPT, total cholesterol and a decrease in alkaline phosphatase in females, in groups dosed with 1000 mg/kg bw/day. Changes were thought to be secondary to effects on the liver.
URINALYSIS: No adverse effects.
NEUROBEHAVIOUR: No adverse effect on sensory activity and locomotor activity.
ORGAN WEIGHTS: At the end of the treatment period there was an increase in liver weights in males and females, and an increase in kidney weights in males in groups dosed with 1000 mg/kg bw/day.
GROSS PATHOLOGY: An increase in liver weights was also observed in females of the 1000 mg/kg bw/day group. During necropsy, enlarged liver was also observed at the end of the recovery period in males and females dosed with 1000 mg/kg bw/day.
HISTOPATHOLOGY: Centrilobular hepatocyte hypertrophy in males and females, and basophilic renal tubules in males at the end of the administration period in the 1000 mg/kg bw/day group. There was also an increase in acidophilic bodies and hyaline droplets observed in males in the 200 mg/kg bw/day group. The basophilic renal tubules in males, and increased relative liver weight in females in the highest dose group were still present at the end of the recovery period. However, the effects in the liver appeared to be reversible, as weights were reducing and histopathological changes were not apparent by the end of the recovery period. - Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on liver hypertrophy at 1000 mg/kg bw/day. Kidney effects assumed not relevant to humans.
- Critical effects observed:
- not specified
- Conclusions:
- In a 28-day repeated dose oral gavage study, conducted to a national standard method and GLP (reliability score 1), the NOAEL for TESPPS was 200 mg/kg bw/day, based on adverse effects in the liver (enlarged liver accompanied by finding of centrilobular hypertrophy) at the higher dose of 1000 mg/kg bw/day. There were also adverse effects in the kidneys of male rats at 200 and 1000 mg/kg bw/day; however, these appeared to be alpha 2u-globulin-type effects, and have been discounted as not relevant to humans by the author of this EPSR.
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 11.01.1983 to 13.06.1983
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Winkelmann.
- Age at study initiation: Males: 42-49 days. Females: 49-56 days.
- Weight at study initiation: Males: 133-146g. Females: 119-137g.
- Fasting period before study:
- Housing: Macrolon cages type II (one animal/cage)
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: One week.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ±2
- Humidity (%): 50-60
- Air changes (per hr): No data
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 11.01.1983 To: 22.02.1983 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: None required, dosed undiluted (2.15 ml/kg).
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily
- Dose / conc.:
- 2 309 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Five
- Control animals:
- other: Tap water only at same dose volume as treated animals.
- Details on study design:
- - Dose selection rationale: Based on the results of 14 day dose range finding study in rats.
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: To assess reversibility of any adverse effects.
- Post-exposure recovery period in satellite groups: 14 days. - Positive control:
- None
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Twice daily.
- No further details
DETAILED CLINICAL OBSERVATIONS: Yes, including eye, hearing and teeth check.
BODY WEIGHT: Yes
- Time schedule for examinations: Weekly
FOOD CONSUMPTION:
- Food consumption as weekly mean values of five animals per group and sex.
FOOD EFFICIENCY: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: Corneal reflex only, at beginning and end of exposure period.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Prior to first administration and at the end of the study.
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: All
- Parameters checked in table No.1 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Prior to first administration and at the end of the study.
- Animals fasted: No data
- How many animals: All
- Parameters checked in table No.1 were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Weekly
- Dose groups that were examined: All
- Battery of functions tested: reflex (pupillar, pain and corneal) testing. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 2)
HISTOPATHOLOGY: Yes (see table 2) - Other examinations:
- None
- Statistics:
- An analysis of variance was performed on all measured values of the test results of all groups. In addition, the Student t-test was performed in the case of significance.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No deaths and clinical signs of toxicity.
BODY WEIGHT AND WEIGHT GAIN: No effects detected.
FOOD CONSUMPTION: No treatment-related effects detected. One animal was affected by adhesive pleuritis, so food intake was reduced during weeks 4 and 5.
OPHTHALMOSCOPIC EXAMINATION: No effect in corneal reflexes (no other parameter examined).
HAEMATOLOGY: No treatment-related effects.
CLINICAL CHEMISTRY: No treatment-related effects.
NEUROBEHAVIOUR: No effect on reflexes.
ORGAN WEIGHTS: The liver showed an increase in the relative organ weight in both sexes of treated animals. The absolute weight of the left kidneys was significantly different within the female recovery group as a consequence of a low, abnormal kidney weight of two control animals. The weight of both adrenal glands was relatively and absolutely reduced in the male substance treated animals compared with the controls. The differences in liver and adrenal gland weights were reversed by the end of the recovery period.
GROSS PATHOLOGY: No treatment-related effects. In the animal with adhesive pleuritis the subpleural lung parenchyma was partially involved in the disease.
HISTOPATHOLOGY: A number of histopathological changes occurred in treated and control animals that were regarded as unspecific reactions to infections or spontaneous pathology. None of the recovery animals showed these findings. In one animal a regressive change in one testis, expressing a disturbance in spermatogenesis was recorded. There were no such findings in controls, so a treatment-related effect cannot be excluded. However, it is possible that this was a spontaneous change. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 2 309 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant irreversible effects observed at the only dose tested.
- Critical effects observed:
- not specified
- Conclusions:
- In a well conducted and reported 28-day repeated dose toxicity limit study (reliability score 1) conducted according to OECD 407 and GLP, the NOAEL for Reinforcing Agent Si 69 was at least 2309 mg/kg bw/day in rats.
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 21.08.2001 to 27.02.2002
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Health and Welfare (MHW) Guidelines 1986 for a twenty-eight day repeated dose oral toxicity.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited
- Age at study initiation: Five to six weeks.
- Weight at study initiation: Males: 120-154g, Females: 112-143g
- Fasting period before study: None
- Housing: Polypropylene grid-floor cages suspended over trays lined with absorbent paper.
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: Seven days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21±2
- Humidity (%): 55±15
- Air changes (per hr): At least 15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Test material was prepared at the appropriate concentrations as a solution in dried arachis oil BP.
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data
- Concentration in vehicle: 0, 31.6, 158 and 631 mg/ml
- Amount of vehicle (if gavage): No data
- Lot/batch no. (if required): No data
- Purity: No data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples were taken of each test material formulation and were analysed for concentration of Silquest A-1589 silane. The method was not included in the part of the report provided. The results indicated that the prepared formulations were within ±9% of the nominal concentrations.
- Duration of treatment / exposure:
- 28 Days (plus 14 day recovery)
- Frequency of treatment:
- Daily
- Dose / conc.:
- 61 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 305 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 221 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Five
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Range-finding study.
- Rationale for animal assignment: Random
- Post-exposure recovery period in satellite groups: Recovery groups for control and high dose groups to investigate reversibility of any observed adverse effects. - Positive control:
- None
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: All animals were examined for overt signs of toxicity, ill-health or behavioural change immediately before dosing and one to five hours after dosing during the working week. Animals were observed immediately before dosing and one hour after dosing at weekends and public holidays. During the treatment-free period, animals were observed twice daily, morning and afternoon (once daily at weekends).
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were recorded on Day 0 (the first day of treatment) and on Days 7, 14, 21 and 28, and in recovery group animals on Days 35 and 42. Body weights were also recorded at terminal kill.
FOOD CONSUMPTION AND FOOD EFFICIENCY: Yes
- Food consumption for each cage group was recorded at intervals throughout the study.
WATER CONSUMPTION: Yes
- Time schedule for examinations: Daily for each cage group, by visual inspection of the water bottles for overt changes.
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Non-recovery test and control groups at the end of the treatment period on Day 28, and on all recovery group animals at the end of the treatment-free period (Day 42).
- Anaesthetic used for blood collection: No data
- Animals fasted: No
- Parameters checked in table [No.1] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Non-recovery test and control groups at the end of the treatment period on Day 28, and on all recovery group animals at the end of the treatment-free period (Day 42).
- Animals fasted: No
- Parameters checked in table [No.1] were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: All non-recovery test and control animals during week 4 and on all recovery group animals during week 6.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked in table [No.1] were examined.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 2)
HISTOPATHOLOGY: Yes (see table 2) - Statistics:
- Data were processed to give group mean values and standard deviation where appropriate.
Haematological, blood chemical, organ weight (absolute and relative to terminal bodyweight), weekly body weight gain and quantitative urinalytical data were assessed for non-recovery groups, and dose-response relationships by linear regression analysis followed by one way analysis of variance (ANOVA) incorporating Levene's test for homogeneity of variance. Where variances were shown to be homogenous, pairwise comparisons were conducted using Dunnett's test. In the case of recovery group data a two-tailed t-test incorporating Levene's test for homogeneity of variance was performed. Where Levene's test showed unequal variances among either non-recovery or recovery group data, the affected parameters were analysed using non-parametric methods: Kruskal-Wallis ANOVA and Mann-Whitney 'U' test. - Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: There were no deaths during the study. Animals of either sex treated with 1221 mg/kg bw/day showed increased salivation either before or for up to ten minutes after dosing from Day 9 onwards together with associated isolated incidents of red/brown staining of the external body surface and generalised fur loss. These findings had regressed in recovery group animals following cessation of treatment. Observations of this nature are often reported when the test material formulation is unpalatable or mildly irritant and, as such, are considered not to represent systemic toxicity. No treatment-related findings were detected in animals treated with 305 or 61 mg/kg bw/day.
BODY WEIGHT AND WEIGHT GAIN: No adverse effects on body weight and body weight gain were observed.
FOOD CONSUMPTION AND FOOD EFFICIENCY: There were no adverse effects on food consumption or food efficiency.
WATER CONSUMPTION: Daily visual inspection of water bottles revealed no intergroup differences.
HAEMATOLOGY: No toxicologically significant effects were detected in the haematological parameters measured.
CLINICAL CHEMISTRY: No toxicologically significant effects were detected in the blood chemistry parameters measured.
URINALYSIS: No toxicologically significant effects were detected in the urinalysis parameters measured.
ORGAN WEIGHTS: (see Table 3) Males treated with 1221 or 305 mg/kg bw/day showed a slight but statistically significant increase in absolute liver weight with a statistically significant increase in relative (to terminal body weight) liver weight noted in both sexes treated with 1221 and 305 mg/kg bw/day. In most cases individual values were within the normal range for rats of the strain and age used, and there were no histopathological correlates. However, the weight increases were apparently dose-related and an association with treatment could not be ruled out. Other isolated findings were considered to be incidental and unrelated to treatment.
GROSS PATHOLOGY: No treatment-related macroscopic abnormalities were found.
HISTOPATHOLOGY: Treatment-related kidney changes were detected. A higher incidence and marginally greater general severity of groups of basophilic tubules were observed for male rats dosed at 1221 mg/kg bw/day. Although this effect was equivocal it was to some extent confirmed by a similar residual finding among recovery group 1221 mg/kg bw/day male rats. - Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 221 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Dose descriptor:
- NOEL
- Effect level:
- ca. 61 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Elevated liver weights with no histopathological changes, and most individual values within the normally expected range, and basophilic tubules in male kidneys without any renal dysfunction or degenerative changes at the two higher doses.
- Critical effects observed:
- not specified
- Conclusions:
- In a GLP study (reliability score 2) conducted according to MHW test guidelines administration of Silquest A-1589 Silane by oral gavage for 28 days gave a NOAEL of 1221 mg/kg bw/day and a NOEL of 61 mg/kg bw/day in rats. The test substance was similar to the registered substance but contained a higher proportion of an S3 isomer.
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 20.04.1999 to 10.02.2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan
- Age at study initiation: Five weeks.
- Weight at study initiation: Males: 139.5-162.9 g. Females: 119.6-144.0 g.
- Fasting period before study:
- Housing: Individually in hanging stainless steel cage with wire mesh floor.
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: yes, but period not stated.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 ± 2
- Humidity (%): 55 ± 10
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 17.06.1999 To: 29.07.1999 - Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: The test substance was weighed accurately and dissolved with olive oil to make a 10 %w/v solution from which the 2.0, 0.4 and 0.08 % w/v solutions were prepared. 10 and 2.0 %w/v solutions were prepared weekly, and the 0.4 and 0.08 % w/v were prepared prior to use.
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data.
- Concentration in vehicle: 10, 2.0, 0.4 and 0.08 %w/v.
- Amount of vehicle (if gavage): No data
- Lot/batch no. (if required): 004RRA
- Purity: No data - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 28 days (plus a 14 day recovery period with no treatment for the high dose group)
- Frequency of treatment:
- Daily
- Dose / conc.:
- 8 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 40 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Six
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on the results of a 14 day preliminary study.
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: No data
- Post-exposure recovery period in satellite groups: yes, vehicle only and high dose group recovery groups.
- Section schedule rationale (if not random): No data - Positive control:
- None
- Observations and examinations performed and frequency:
- The day of the initiation of dosing was defined as Day 1, and the day before as Day -1. The week of the initiation of the dosing period was defined as Week 1. Also, the next day of the final dosing was defined as Recovery day 1, and the week of the initiation of the recovery period as Recovery week 1.
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least daily.
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes
- Time schedule for examinations: Before dosing on Day -2, then on Days 1, 3, 8, 12, 17, 21, 26 and 28, and during the recovery period on Days 1, 5, 10 and 14. Plus immediately before necropsy for calculation of relative organ weights.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/rat/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the termination of dosing and at the end of the recovery period.
- Anaesthetic used for blood collection: Yes (ether).
- Animals fasted: Yes, overnight (16-20 hours).
- How many animals: All survivors.
- Parameters checked in table 1 were examined. In addition a myelogram was performed as haematological abnormalities were noted in the preliminary toxicity study. Thin bone marrow smears were prepared from the left femurs in the first three animals of each group at the terminal necropsy of the dosing and recovery periods, and examined in the 1000 mg/kg and vehicle control groups on the terminal necropsy of the dosing period. Parameters examined were: myerobrasts, promyelocytes, myelocytes, metamyelocytes, stab neutrophils, segmented neutrophils, eosinophils, basophils, lymphocytes, plasmacytes, megakaryocytes, retoperitheliums, mastocytes, monocytes, proerythroblasts, basoerythroblasts, polychromatic erythroblasts, neuerythroblasts, and myeloblast series/erythroblasts series (M/E ratio).
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the termination of dosing and at the end of the recovery period.
- Animals fasted: Yes, overnight (16-20 hours).
- How many animals: All survivors.
- Parameters checked in table 1 were examined.
URINALYSIS: Yes
- Time schedule for collection of urine: At termination of the dosing and recovery periods.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
- Parameters checked in table 1 were examined.
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 2)
HISTOPATHOLOGY: Yes (see table 2) - Statistics:
- Data regarding body weights, food intakes, haematology, clinical chemistry, urinalysis and organ weights were analysed using the Bartlett's test for homogeneity of variance. If the variances were homogeneous at a significance level of 5%, one way analysis of variance was performed. If there was a significant difference in this analysis, the difference between the vehicle group and each of the treatment groups was analysed by the Dunnett's test (equal number of data). If the variances were not homogeneous the Kruskal-Wallis's test was used. If there was a significant difference in this analysis, the difference between the vehicle control group and each of the treatment groups was analysed by the nonparametric Dunnett's test (equal number of data).
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: During the dosing period salivation was observed in males of the vehicle control group (8/12), 8 mg/kg bw/day group (3/6), 40 mg/kg bw/day group (5/6), 200 mg/kg bw/day group (6/6) and 1000 mg/kg bw/day group (12/12). In females the salivation was observed in the vehicle control group (4/12), 8 mg/kg bw/day group (3/6), 40 mg/kg bw/day group (3/6), 200 mg/kg bw/day group (5/6) and 1000 mg/kg bw/day group (12/12). Staining around the nose and mouth was observed in 3/12 males and 1/12 females in the high dose group. Hair loss was also observed in the high dose males (2/12). These clinical signs were not observed in the recovery period. Salivation is commonly observed in gavage studies.
BODY WEIGHT AND WEIGHT GAIN: There were no abnormalities in either the dosing or recovery periods.
FOOD CONSUMPTION: There were no abnormalities in either the dosing or recovery periods.
HAEMATOLOGY: There were no abnormalities in males. At termination of dosing there was a decrease in red blood cell count, and an increase in activated thromboplastin time in high dose females. At the end of the recovery period an increase in red blood cell count and a decrease in mean corpuscular haemoglobin was noted in the high dose group.
CLINICAL CHEMISTRY: At the end of the dosing period there was an increase in calcium level in the high dose group males. In high dose females there were increases in GPT and gamma-GTP activities, total cholesterol, total protein, albumin levels, and a decrease in alkaline phosphatase activity. There was also a tendency towards increased GPT activity due to an increase in one animal of the 200 mg/kg bw/day. There were no such findings at the end of the recovery period.
URINALYSIS: There was a tendency towards increased ketone bodies in the high dose groups for males and females, and the 200 mg/kg bw/day group for females at the end of the dosing period. There were no such findings at the end of the recovery period.
ORGAN WEIGHTS: Small testes were observed in one male of the vehicle control group at the end of the recovery period, but these were not analysed statistically as they were considered to be a malformation. In males at termination of dosing, increases in relative liver weights were noted in the 200 and 1000 mg/kg bw/day groups. Decreased absolute testis weights were noted in the 8 and 40 mg/kg bw/day groups, and decreased relative kidney weights were noted in the 200 mg/kg bw/day group. In females there was an increase in absolute liver weight in the 200 mg/kg bw/day group, and an increase in absolute and relative liver weights in the 1000 mg/kg bw/day group. There were no such findings at the end of the recovery period.
GROSS PATHOLOGY: At the end of the dosing period males had enlargement (2/6) of the liver and loss of hair (1/6) in the highest dose group. Females of the highest dose group (4/6) had liver enlargement. At the termination of the recovery period. No abnormalities were observed in females, but there was one male of the vehicle control group that had small testes.
HISTOPATHOLOGY: NON-NEOPLASTIC: Table 3 summaries the histopathology findings. - Dose descriptor:
- NOAEL
- Effect level:
- 200 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Critical effects observed:
- not specified
- Conclusions:
- In a well conducted and documented 28-day repeated dose oral gavage study (reliability score 1) conducted according to OECD 407 and GLP, the NOAEL for Si-75 was 200 mg/kg bw/day in rats. This was based on histopathological changes in the liver and kidney.
Referenceopen allclose all
Table 3: Incidence of selected pathologies
Parameter |
n=5/sex |
Dose level (mg/kg bw/day) |
|||||
Control |
61 |
305 |
1221 |
Recovery control |
Recovery 1221 |
||
Heart: focal myocarditis (minimal) |
M |
(2/5) |
N/E |
N/E |
(2/5) |
N/E |
N/E |
F |
(1/5) |
N/E |
N/E |
(1/5) |
N/E |
N/E |
|
Kidney: groups of basophilic tubules (minimal or slight) |
M |
- |
(4/5) |
(2/5) |
(3/5) 2/5 |
(2/5) |
(2/5) 3/5 |
F |
(1/5) |
- |
(1/5) |
(2/5) |
- |
(4/5) |
|
Kidney: hydronephrosis (minimal or slight) |
M |
- |
- |
- |
(1/5) |
1/5 |
- |
F |
- |
- |
- |
(1/5) |
- |
- |
|
Kidney: cortical scarring |
M |
- |
- |
(1/5) |
- |
- |
- |
F |
- |
- |
- |
- |
- |
- |
|
Kidney: corticomedullary mineralization (minimal) |
M |
- |
- |
- |
- |
- |
- |
F |
- |
- |
- |
(1/5) |
- |
(1/5) |
|
Liver: mononuclear cell foci (minimal) |
M |
(5/5) |
N/E |
N/E |
(5/5) |
N/E |
N/E |
F |
(5/5) |
N/E |
N/E |
(5/5) |
N/E |
N/E |
|
Spleen:extramedullary haemopoiesis (minimal or slight) |
M |
(3/5) 2/5 |
N/E |
N/E |
(5/5) |
N/E |
N/E |
F |
5/5 |
N/E |
N/E |
(5/5) |
N/E |
N/E |
N/E not examined
- no change
( ) statistically significant change not considered to be toxicologically significant.
Table 3: Incidence of selected pathologies
Parameter |
n=6/sex |
Dose level (mg/kg bw/day) |
|||||||
Control |
8 |
40 |
200 |
1000 |
Recovery control |
Recovery 1000 |
|||
Liver enlargement |
M |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
|
F |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
||
Testes - small |
M |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
|
F |
- |
- |
- |
- |
- |
- |
- |
||
Skin - Loss of hair |
M |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
|
F |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Liver – Centrilobular hypertrophy of hepatocytes |
M |
0 |
- |
- |
- |
4/6 (+) |
0 |
0 |
|
F |
0 |
- |
- |
- |
3/6 (+) |
0 |
0 |
||
Centrilobular lipid droplets of hepatocytes |
M |
0 |
- |
- |
0 |
0 |
0 |
0 |
|
F |
0 |
- |
- |
3/6 (+) |
0 |
0 |
0 |
||
Disseminated microgranuloma |
M |
1/6 (+) |
- |
- |
1/6 (+) |
0 |
1/6 (+) |
0 |
|
F |
0 |
- |
- |
0 |
2/6 (+) |
1/6 (+) |
0 |
||
Periportal lipid droplets of hepatocytes |
M |
1/6 (+) |
- |
- |
0 |
0 |
0 |
0 |
|
F |
1/6 (+), 1/6(++) |
- |
- |
1/6 (±), 2/6 (+) |
3/6 (+), 2/6 (++) |
0 |
0 |
||
Periportal microgranuloma |
M |
0 |
- |
- |
0 |
0 |
0 |
0 |
|
F |
1/6 (++) |
- |
- |
1/6 (+) |
2/6 (+) |
0 |
0 |
||
Single cell necrosis of hepatocytes |
M |
0 |
- |
- |
0 |
0 |
0 |
1/6 (+) |
|
F |
0 |
- |
- |
0 |
0 |
0 |
2/6 (+) |
||
Kidney – Basophilic tubules |
M |
0 |
- |
- |
0 |
4/6 (+) |
0 |
1/6 (±), 2/6 (+) |
|
F |
0 |
- |
- |
0 |
1/6 (±) |
0 |
1/6 (±), 2/6 (+) |
||
Increased eosinophilic bodies |
M |
0 |
- |
- |
0 |
0 |
0 |
2/6 (±) |
|
F |
0 |
- |
- |
0 |
0 |
0 |
0 |
||
Increased hyaline droplets |
M |
0 |
- |
- |
0 |
1/6 (± ), 1/6 (+) |
0 |
3/6 (±) |
|
F |
0 |
- |
- |
0 |
0 |
0 |
0 |
||
Subcapsular solitary cyst |
M |
1/6 (+) |
- |
- |
0 |
0 |
0 |
0 |
|
F |
0 |
- |
- |
0 |
0 |
0 |
0 |
||
Testes – diffuse atrophy of seminiferous tubules |
M |
- |
- |
- |
- |
- |
1/1 (+++) |
- |
|
F |
- |
- |
- |
- |
- |
- |
- |
||
Leydig cell hyperplasia |
M |
- |
- |
- |
- |
- |
1/1 (++) |
- |
|
F |
- |
- |
- |
- |
- |
- |
- |
||
Skin – scab formation |
M |
- |
- |
- |
- |
1/1 (+) |
- |
- |
|
F |
- |
- |
- |
- |
1/1 |
- |
- |
||
± very slight, + slight, ++ moderate, +++ severe
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 200 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No repeated dose toxicity data are available for the registered substance, therefore this endpoint is addressed using weight of evidence from reliable data for a number of related substances. The composition of these related substances includes different concentrations of both isomers present in the registration substance, and the available data indicate that there are no differences in systemic toxicity for constituents with different numbers of sulfur atoms in a (poly)sulfide chain. Since the three test substances cover the composition range of the registered substance, and no significant adverse effects were seen in any study up to a high dose level of 1000 mg/kg/day, additional testing with the registration substance itself is not warranted.
Four relevant 28-day oral toxicity studies are available on which to base a weight of evidence approach for the registered substance.
There is a testing proposal for a 90 -day repeated dose toxicity test with polysulfides, bis[3-(triethyoxysilyl)propyl (CAS No 211519-85-6).
Justification for read-across from Polysulfides, bis[3-(triethoxysilyl) propyl] (Polysulfides; CAS 211519-85-6) and 4,4,13,13-tetraethoxy-3,14-dioxa-8,9-dithia-4,13-disilahexadecane (S2; CAS 56706-10-6)
(a) Structural similarity
Both the registration substances and the read-across substances are structurally similar; all contain bis[3-(triethoxysilyl)propyl]- structures with the two (triethoxysilyl)propyl groups linked by di- or polysulfide groups. Details on the composition of the three materials is given in Section 1.4 of the CSR but in summary the registration substance is a multiconstituent substance comprising 50-65% by weight of disulfide, 30-40% by weight of trisulfide and 5-15% tetrasulfide. S2 is a monoconstituent substance comprising >80% by weight of disulfide, with approximately 10-20% of the trisulfide as an impurity whereas Polysulfides is multiconstituent comprising a mixture of di- (S2, 15-25% w/w), tri- (S3, 30-35% w/w) and tetrasulfides (S4, 20-30% w/w). Additional information including structural diagrams is included in the attached report.
S2, S3 and S4 can be considered as toxicologically equivalent; this is discussed further in (c) and (d).
(b) Similar physicochemical characteristics
The key physicochemical parameters of the substances are summarised in the attached document. The substances all hydrolyse, and the products of hydrolysis are bis(3-(trihydroxysilyl)propylsulfides (with a varying number of sulfur atoms) and ethanol. The key physicochemical properties of the silanol hydrolysis products are also included in the attached document. Information on the physicochemical properties of the individual constituents can be found in Section 1.4.
Summary of key physicochemical parameters
Abbreviation |
Low purity S21 |
S2 |
S2/S3 |
Polysulfides |
CAS Number |
n/a |
56706-10-6 |
n/a |
211519-85-6 |
EC number |
n/a |
260-350-7 |
915-748-1 |
915-673-4 |
Status |
Not for registration |
Registered |
Registered |
Registered |
Chemical Name |
n/a1 |
4,4,13,13-tetraethoxy-3,14-dioxa-8,9-dithia-4,13-disilahexadecane |
Reaction mass of 4,4,13,13-tetraethoxy-3,14-dioxa-8,9-dithia-4,13-disilahexadecane and 4,4,14,14-tetraethoxy-3,15-dioxa-8,9,10-trithia-4,14-disilaheptadecane |
Reaction mass of 4,4,15,15-tetraethoxy-3,16-dioxa-8,9,10,11-tetrathia-4,15-disilaoctadecane and 4,4,14,14-tetraethoxy-3,15-dioxa-8,9,10-trithia-4,14-disilaheptadecane and 4,4,13,13-tetraethoxy-3,14-dioxa-8,9-dithia-4,13-disilahexadecane |
Composition |
5-10% S1; 65-70% S2; 15-20% S3 |
80-90% S2 |
50-65% S2; 30-40% S3 |
15-25% S2; 30-35% S3; 20-30% S4; 15-30% Sn n>4[1] |
Molecular weight |
443-507 g mol-1 |
475 g mol-1 |
475-507 g mol-1 |
475-539 |
log Kow(parent) |
4.2-5.2 (prediction) |
5.2 (prediction) |
5.2 (prediction) |
5.2 (prediction) |
log Kow(silanol hydrolysis product) |
-3.0 (prediction) |
-3.0 (prediction) |
-3.0 (prediction) |
-3.0 (prediction) |
Water sol (parent) |
<1 mg/l (prediction) |
≤1 mg/l (measured) |
1 mg/l (prediction) |
<1 mg/l (measured) |
Water sol (silanol hydrolysis product) |
1E+06 mg/l (prediction) The concentration dissolved in water is limited to about 1000 mg/l by condensation reactions. |
1E+06 mg/l (prediction) The concentration dissolved in water is limited to about 1000 mg/l by condensation reactions. |
1E+06 mg/l (prediction) The concentration dissolved in water is limited to about 1000 mg/l by condensation reactions. |
1E+06 mg/l (prediction) The concentration dissolved in water is limited to about 1000 mg/l by condensation reactions. |
Vapour pressure (parent) |
9 Pa (read-across, supported by predictions) |
9 Pa (measured) |
9 Pa (read-across, supported by predictions) |
9 Pa (read-across, supported by predictions) |
Vapour pressure (silanol hydrolysis product) |
2.9E-05 Pa at 25°C (calculated) |
2.9E-05 Pa at 25°C (calculated) |
2.9E-05 Pa at 25°C (calculated) |
2.9E-05 Pa at 25°C (calculated) |
Hydrolysis t1/2at pH 7 and 20-25°C |
40-90 hours (prediction) |
40-90 hours (prediction) |
40-110 hours (prediction) |
40 – 130 hours (prediction) |
Hydrolysis t1/2at pH 2 and 37.5°C |
11-14 seconds (prediction) |
11 - 14 seconds (prediction) |
11-18 seconds (prediction) |
11-20 seconds (prediction) |
[1]The substance tested in the OECD 414 study with Polysulfides contained 18% S2; 30% S3; 24% S4; 27% Sn where n > 4
Due the very similar chemical structures, the registration and read-across substances are predicted to have near identical physicochemical properties.
The substances hydrolyse very rapidly to silanols and ethanol at pH 2 and 37.5°C (the conditions relevant for oral exposure). The silanol hydrolysis products are predicted to have near identical physicochemical properties.
(c) Similar toxicokinetics
Based on the predicted physicochemical properties it can be inferred that the substances in the sulfidosilane group behave similarly with respect to adsorption, distribution and excretion. The toxicokinetic properties of S2, reaction mass S2/S3 and polysulfides have been predicted based on the physicochemical properties and estimated using pharmacokinetic or toxicokinetic (PBTK) prediction models. See Section 5.1.3 for more information.
(d) Similar acute and repeated dose systemic toxicity
Acute oral and dermal toxicity studies are available for both read-across substances and for low purity S2. No mortalities or systemic effects were observed with either substance in any of the studies, at doses greater than or equal to 2000 mg/kg. Furthermore, there were no effects in an acute inhalation study with the read-across substance. Together these results indicate that the sulfidosilanes have a low acute toxicological profile.
Four relevant 28-day oral toxicity studies are available, two on each of the read-across substances. These are summarised below.
In the first study with CAS 56706-10-6 (Hita Labs., 2000a) four dose groups, a recovery group and a vehicle control group were examined. The high dose was 1000 mg/kg bw/day, and the three lower doses 200, 40 and 8 mg/kg bw/day and a high dose (1000 mg/kg bw/day) recovery group. The test material contained >80% of the S2 constituent, and small amounts of the monosulfide (S1) and polysiloxane impurities. A 14-day recovery period was included. In this study no deaths occurred, there were no abnormalities in clinical signs, body weights and food intakes during the dosing period. The NOAEL determined in this study was 200 mg/kg bw/day based on the histopathological changes centrilobular hypertrophy of the hepatocytes and basophilic tubules in the kidney in the 1000 mg/kg bw/day males and females, and hyaline droplets in the kidney in the 1000 mg/kg bw/day males, and periportal lipid droplets of the hepatocytes in the 1000 mg/kg bw/day females.
In the recovery test, basophilic tubules in the kidney of male and females, and increased hyaline droplets in the kidney of males remained in the 1000 mg/kg bw/day groups. The other treatment -related changes at the termination of the dosing period were not observed after recovery period. The histopathological effects in the high dose group (1000 mg/kg bw/day) are of minor toxicological relevance and did not result in any clinical symptoms. The experience of the lead registrant is that 4 weeks or longer are better to demonstrate reversibility of effects. If a minor toxicological effect is reversible it is not an adverse effect. In summary this study gives no indication of a severe toxicological concern even in the high dose group. Although the study was conducted according to current OECD test guideline and GLP, it is assigned reliability 2 because a thorough histopathological investigation of required tissues was not carried out.
In a second study (SafePharm, 2002), which was conducted in accordance with Japanese national guidelines for 28-day oral toxicity testing, the test material contained mainly the S2 and S3 constituents, with a small amount of S1 impurity. Dose levels were 0, 61, 305, 1221 mg/kg bw/day. There were no deaths, significant clinical signs or effects on body weight, urinalysis, clinical chemistry and haematological parameters measured. Males treated with 1221 or 305 mg/kg bw/day showed a slight but statistically significant increase in absolute liver weight with a statistically significant increase in relative (to terminal body weight) liver weight noted in both sexes treated with 1221 and 305 mg/kg bw/day. In most cases individual values were within the normal range for rats of the strain and age used, and there were no histopathological correlates. However, the weight increases were apparently dose-related and an association with treatment could not be ruled out. Other isolated findings were considered to be incidental and unrelated to treatment.
Treatment-related kidney changes were detected. A higher incidence and marginally greater general severity of groups of basophilic tubules were observed for male rats dosed at 1221 mg/kg bw/day. Although this effect was equivocal it was to some extent confirmed by a similar residual finding among recovery group 1221 mg/kg bw/day male rats. The NOAEL was judged to be 1221 mg/kg bw/day and the NOEL was 61 mg/kg bw/day.
Two 28-day studies are also available for the related substance polysulfides, bis[3-(triethoxysilyl)propyl] (CAS 211519 -85 -6) which is a reaction mass containing principally the S2 (15-60%), S3 (25-40%) and S4 (5-30%) constituents.
In the first (Hita Labs., 2000b) four dose groups, a recovery group and a vehicle control group were examined. The high dose was 1000 mg/kg bw/day, and the three lower doses 200, 40 and 8 mg/kg bw/day and a high dose (1000 mg/kg bw/day) recovery group. The recovery period was 14 days. In this study no death occurred, there were no abnormalities in clinical signs, body weights and food intakes during the dosing period. The NOAEL determined in this study was 200 mg/kg/day based on the histopathological changes centrilobular hypertrophy of the hepatocytes and basophilic tubules in the kidney in the 1000 mg/kg bw/day males and females, and hyaline droplets in the kidney in the 1000 mg/kg bw/day males, and periportal lipid droplets of the hepatocytes in the 1000 mg/kg bw/day females.
In the recovery test, basophilic tubules in the kidney of male and females, and increased hyaline droplets in the kidney of males remained in the 1000 mg/kg bw/day groups. The other treatment-related changes at the termination of the dosing period were not observed after recovery period.
In the other study with the polysulfides (Degussa AG, 1983), a limit test at 2309 mg/kg bw/day was carried out. The only treatment related effects were related to organ weights. There was an increase in relative liver weight in both sexes of treated animals. The absolute weight of the left kidneys was significantly different within the female recovery group as a consequence of a low, abnormal kidney weight of two control animals. The weight of both adrenal glands was relatively and absolutely reduced in the male substance treated animals compared with the controls. The differences in liver and adrenal gland weights were reversed by the end of the recovery period. The NOAEL was reported as 2309 mg/kg bw/day.
There were no adverse effects on any of the reproductive organs examined in any of the studies described above.
The studies clearly show that the substances tested have a similar toxicological profile.
Summary of repeated dose toxicity data
Test substance |
Dose levels |
Recovery group included? |
Results |
Reference |
S2 |
8, 40, 200 and 1000 mg/kg bw/day |
Yes |
NOAEL: 200 mg/kg bw/day
Basis:centrilobular hypertrophy of the hepatocytes and basophilic tubules in the kidney in the 1000 mg/kg bw/day males and females, and hyaline droplets in the kidney in the 1000 mg/kg bw/day males (effect not relevant for humans), and periportal lipid droplets of the hepatocytes in the 1000 mg/kg bw/day females.
Recovery: basophilic tubules in the kidney of male and females, and increased hyaline droplets in the kidney of males remained in the 1000 mg/kg bw/day groups. The other treatment -related changes at the termination of the dosing period were not observed after recovery period. |
Hita Laboratory (2000a) |
S2 |
0, 61, 305, 1221 mg/kg bw/day |
No |
NOAEL: ca. 1221 mg/kg bw/day
Basis: Elevated liver weights with no histopathological changes, and most individual values within the normally expected range, and basophilic tubules in male kidneys without any renal dysfunction or degenerative changes were not considered adverse effects. |
McRae, L., Mullee, D. and Brooks, P.N. (2002) |
Polysulfides |
8, 40, 200 and 1000 mg/kg bw/day |
Yes |
NOAEL: 200 mg/kg bw/day
Basis: liver hypertrophy at 1000 mg/kg bw/day. Kidney effects assumed not relevant to humans.
Recovery:basophilic tubules in the kidney of male and females, and increased hyaline droplets in the kidney of males remained in the 1000 mg/kg bw/day groups. The other treatment-related changes at the termination of the dosing period were not observed after recovery period. |
Hita Laboratory (2000b) |
Polysulfides |
2309 mg/kg bw/day (limit test) |
Yes |
NOAEL: ≥2309 mg/kg bw/day
Basis: No irreversible adverse effects.
Recovery: differences in liver and adrenal gland weights were reversed by the end of the recovery period |
Degussa AG (1983) |
Consideration of possible mixture effects
When considering the toxicity of mixtures, it is necessary to consider the possibility that the toxicity of the mixture is greater than would be expected based on the sum of the constituents (synergistic effects). The sulfidosilane substances Polysulfides, S2/S3 reaction mix and low purity S2 are multiconstituent substances. However, mixture effects are considered unlikely based on the high degree of similarity between the different constituents. The structural similarity of the constituents makes it probable that toxicity is exerted by each constituent of the multiconstituent substances with the same mode of action. This would make the effects additive, rather than synergistic. Evidence of this can be seen in the 28-day repeated dose toxicity studies where both the type of effects (adaptive changes in liver and kidney) and the effect levels seen in studies on S2, low purity S2 and Polysulfides are very similar.
If mixture effects did occur for the Polysulfides, this would probably make the Polysulfides more toxic than the submission substance. It is very unlikely that mixture effects would lead to a reduction in toxicity. Therefore, the proposed read-across is considered to be conservative.
(e) Justification of read across conclusions
The structural similarities between the source and the target substances and the similarities in their breakdown products presented above support the read-across hypothesis. Adequate, reliable and available scientific information indicates that the source and target substances and their abiotic degradation products follow similar metabolic pathways resulting in identical products of metabolism, and therefore have similar toxicity profiles.
The constituents of the target substance are constituents of the source substance polysulfides, and are also present in the source substances S2 and low purity S2. Information on hydrolysis indicates that, under the conditions in the stomach in oral toxicity studies, source and target substances are subject to rapid hydrolysis to ethanol, and to silanol hydrolysis products that differ only in the number of sulfur atoms in the sulfide bridge. Thus, systemic exposure following oral administration will be predominantly to these breakdown products.
Information on sulfur metabolism indicates that the substances and the silanol hydrolysis products of source and target substances will follow similar biotransformation pathways producing identical metabolites.
No classification and labelling criteria are fulfilled by the source or target substances.
Justification for classification or non-classification
No serious adverse effects were observed in repeated dose oral toxicity studies in the rat with closely related test substances. Based on this weight of evidence, the registered substance does not require classification for Specific Target Organ Toxicity according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.